India, May 12 -- Disparities in maternal healthcare outcomes remain stark across the globe according to 2020 statistics. Extreme Risks in Africa Sub-Saharan nations face the highest risks for expec... Read More
India, May 12 -- Global healthcare initiatives have driven a consistent reduction in maternal mortality ratios across the world over the last twenty years. Early Millennium Improvements Starting at... Read More
India, May 12 -- World Development Indicators for 2023 reveal a staggering divide in female survival rates between different global regions. Leaders in Longevity Monaco currently holds the highest ... Read More
India, May 12 -- World Development Indicators for 2023 highlight a profound divide in male survival rates, showing that geographical location remains a primary determinant of lifespan. Longevity Lead... Read More
Singapore, May 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... Read More
Singapore, May 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... Read More
Singapore, May 12 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combine... Read More
Singapore, May 12 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combine... Read More
Singapore, May 12 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the pos... Read More
Singapore, May 12 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507)... Read More